|Table of Contents|

Expression of miR-197,miR-221 and miR-222 in thyroid cancer tissues of different pathological types and stages and their clinical significance

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 03
Page:
456-460
Research Field:
Publishing date:

Info

Title:
Expression of miR-197,miR-221 and miR-222 in thyroid cancer tissues of different pathological types and stages and their clinical significance
Author(s):
FENG Yujun1; WANG Linna1; ZHAO Zhengli1; LIU Hainan2; WEI Wei3; XU Shasha1; LI Meiyun1; LEI Yong1
1.Hengshui People's Hospital,Hebei Hengshui 053000,China;2.Hebei Rehabilitation Center for the Disabled,Hebei Shijiazhuang 050081,China;3.The Sixth People's Hospital of Hengshui,Hebei Hengshui 053000,China.
Keywords:
thyroid cancer; pathological classification; staging; miR-197; miR-221; miR-222
PACS:
R736.1
DOI:
10.3969/j.issn.1672-4992.2024.03.011
Abstract:
Objective:To observe the expression of miR-197,miR-221 and miR-222 in different pathological types and stages of thyroid cancer,and analyze their significance in the diagnosis of thyroid cancer.Methods:The clinical data of 92 patients with thyroid cancer in our hospital from January 2020 to December 2022 were retrospectively analyzed.All patients underwent pathological examination of thyroid cancer tissues and adjacent tissues,and the expression levels of miR-197,miR-221 and miR-222 were determined by quantitative reverse transcription-polymerase chain reaction(RT-PCR),and the miR-197,miR-222 in patients with different pathological types and stages were compared.Results:The expressions of miR-197,miR-221 and miR-222 in thyroid cancer tissues were higher than those in adjacent tissues(t=14.696,14.004 and 15.351,P＜0.05).The expressions of miR-197,miR-221 and miR-222 in patients with lymph node metastasis,undifferentiated carcinoma and stage Ⅲ-Ⅳ thyroid cancer were higher than those in patients without lymph node metastasis,papillary carcinoma/medullary carcinoma/follicular carcinoma and stage Ⅰ-Ⅱ thyroid cancer,respectively(P＜0.05).Logistic regression analysis showed that the high expression of miR-197,miR-221 and miR-222 was a risk factor for lymph node metastasis,undifferentiated cancer and stage Ⅲ-Ⅳ thyroid cancer(OR>1,P＜0.05).Conclusion:The expressions of miR-197,miR-221 and miR-222 are different in different pathological types and stages of thyroid cancer,which will help to judge whether thyroid cancer has lymph node metastasis,different pathological types and clinical stages.

References:

［1］XU M,LIN B,ZHENG D,et al.LEM domain containing 1 promotes thyroid cancer cell proliferation and migration by activating the Wnt/β-catenin signaling pathway and epithelial-mesenchymal transition［J］.Oncol Lett,2021,21(6):442.
［2］吴春晓,吴梦吟,付晨,等.2016年上海市甲状腺癌发病和死亡情况与2002-2016年间变化趋势分析［J］.外科理论与实践,2022,27(1):58-65. WU CX,WU MY,FU C,et al.Incidence and death of thyroid cancer in Shanghai in 2016 and trend analysis between 2002 and 2016［J］.Surgery Theory and Practice,2022,27(1):58-65.
［3］ZHAO Y,WANG H,WU C,et al.Construction and investigation of lncRNA-associated ceRNA regulatory network in papillary thyroid cancer［J］.Oncology reports,2018,39(3):1197-1206.
［4］LIU T,YOU X,SUI J,et al.Prognostic value of a two-microRNA signature for papillary thyroid cancer and a bioinformatic analysis of their possible functions［J］.J Cell Biochem,2018,120(5):7185-7198.
［5］JIAO ZS,ZHANG HN.Establishment and analysis of miRNA prognostic risk model of papillary thyroid cancer based on TCGA database［J］.Cancer Prevention and Treatment Research,2020,47(4):262-267.
［6］YE F,GAO G,ZOU Y,et al.circFBXW7 inhibits malignant progression by sponging miR-197-3p and encoding a 185-aa protein in triple-negative breast cancer［J］.Mol Ther Nucleic Acids,2019,8(18):88-98.
［7］LIU S,WANG Z,LIU Z,et al.miR-221/222 activate the Wnt/β-catenin signaling to promote triple negative breast cancer［J］.J Mol Cell Biol,2018,10(4):302-315.
［8］SHEIKHOLESLAMI S,SHABANI N,SHIVAEE S,et al.Overexpression of miR-129-1,miR-146b,miR-183,and miR-197 in follicular thyroid carcinoma and adenoma tissues［J］.Mol Cell Probes,2020,34(51):101536.
［9］赖敬波,王薇,郭志华,等.甲状腺癌患者miR-146和miR-221/222的表达及与甲状腺癌侵袭转移的关系［J］.兰州大学学报：医学版,2020,46(4):30-34,40. LAI JB,WANG W,GUO ZH,et al.Expression of miR-146 and miR-221/222 in patients with thyroid cancer and their relationship with invasion and metastasis of thyroid cancer［J］.Journal of Lanzhou University:Medical Edition,2020,46(4):30-34,40.
［10］中华医学会内分泌学分会,中华医学会外科学分会内分泌学组,中国抗癌协会头颈肿瘤专业委员会,等.甲状腺结节和分化型甲状腺癌诊治指南［J］.中华核医学与分子影像杂志,2013,33(2):96-115. Endocrinology Branch of Chinese Medical Association,Endocrinology Group of Surgery Branch of Chinese Medical Association,Head and Neck Tumor Committee of China Anti-Cancer Association,et al.Guidelines for diagnosis and treatment of thyroid nodules and differentiated thyroid cancer［J］.Chinese Journal of Nuclear Medicine and Molecular Imaging,2013,33(2):96-115.
［11］HAO R,HAN P,ZHANG L,et al.Genetic polymorphisms in the PCNXL2 gene are risk factors for thyroid cancer in the Chinese population［J］.Future Oncol,2021,17(34):4677-4686.
［12］JAFARZADEH A,NOORI M,SARRAFZADEH S,et al.MicroRNA-383:A tumor suppressor miRNA in human cancer［J］.Front Cell Dev Biol,2022,10:955486.
［13］王逍遥，吕松岑，白皓宇，等.MicroRNA在骨肿瘤中的研究进展［J］.现代肿瘤医学，2018，26（14）：2302-2304. WANG XY,LYU SC,BAI HY,et al.The progression of microRNA in bone tumors［J］.Modern Oncology，2018，26（14）：2302-2304.
［14］HAGGI M,TOVA D,ADI K,et al.Next-generation sequencing identifies a highly accurate miRNA panel that distinguishes well-differentiated thyroid cancer from benign thyroid nodules［J］.Cancer Epidemiol Biomarkers Prev,2018,27(28):858-863.
［15］CAGLAR O,CAYIR A.Total circulating cell-free miRNA in plasma as a predictive biomarker of the thyroid diseases［J］.J Cell Biochem,2019,120(6):9016-9022.
［16］LIU Y,CHENG P,ZHAO W,et al.MiR-197-3p reduces bortezomib resistance in multiple myeloma by inhibiting IL-6 expression in a MEAF6-dependent manner［J］.Leuk Res,2022,46(114):106785.
［17］云耀峰,梁润,郝灵芳,等.不同病理类型及分期甲状腺癌中miR-221 miR-222 miR-197和miR-346的表达研究［J］.西部医学,2018,30(12):1801-1804,1809. YUN YF,LIANG R,HAO LF,et al.Expression of miR-221 miR-222 miR-197 and miR-346 in different pathological types and stages of thyroid cancer［J］.Western Medicine,2018,30(12):1801-1804,1809.
［18］CAI S,MA J,WANG Y,et al.Biomarker value of miR-221 and miR-222 as potential substrates in the differential diagnosis of papillary thyroid cancer based on data synthesis and bioinformatics approach［J］.Front Endocrinol(Lausanne),2022,12:794490.
［19］GAROFALO M,LEVA G D,ROMANO G,et al.Retraction notice to:miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation［J］.Cancer Cell,2022,40(11):1440.
［20］RUIZ-POZO VA,CADENA ULLAURI S,GUEVARA RAMIREZ P,et al.Differential microRNA expression for diagnosis and prognosis of papillary thyroid cancer［J］.Front Med(Lausanne),2023,10:1139362.
［21］AO XR,LIAO C,MA KM,et al.The relationship between the expression of lncRNA panda and miR-637 and the clinicopathological parameters and prognosis of thyroid cancer［J］.Chinese Medicine Guides,2021,18(19):44-47,67.
［22］HAIRONG H,LEI W,TAO Q,et al.Circular RNA ciRS-7 triggers the migration and invasion of esophageal squamous cell carcinoma via miR-7/KLF4 and NF-κB signals［J］.Cancer Biology & Therapy,2018,20(1):73-80.
［23］BLA B,YING LC,LY A,et al.Corrigendum to "miR-221/222 promote cancer stem-like cell properties and tumor growth of breast cancer via targeting PTEN and sustained Akt/NF-κB/COX-2 activation"［Chem.Biol.Interact.277(2017) 33-42］-ScienceDirect［J］.Chem-Biol Interact,2021,345(25):109556.

Memo

Memo:
2022年河北省医学科学研究课题计划(编号：20220471）
Last Update: 2023-12-29